Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia: The REDUCE-IT trial

Apr 01, 2019

Overview : Trial Reference Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22. Abstract | Full Text Expert Comment Maria Eliane Campos Magalhães and Andréa Araujo Brandão Background A long-standing association... more

Effect of Loading Dose of Atorvastatin Prior to Planned PCI: The SECURE-PCI Randomized Clinical Trial

Apr 18, 2018

Overview : Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. The SECURE-PCI Randomized Clinical Trial   Trial References Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin... more

ODYSSEY Long Term Study

Oct 15, 2014

Overview : The Odyssey Long Term Study evaluated the safety and efficacy of alirocumab (mAb anti-PCSK9) in 2341 patients with heterozygous FH or at high risk for cardiovascular events who were receiving a maximally tolerated dose of statin but who had an... more

LAPLACE-2 TRIAL

Jul 17, 2014

Overview : This is the (proprotein convertase subtilisin-kexin type 9) PCSK9 monoclonal-antibody inhibitor that increases the ability of the liver to clear low-density-lipoprotein cholesterol (LDL-C). According to results of the LAPLACE-2 trial -presented on March 30 during the ACC 2014 in Washington,... more